Pharmacokinetics and pharmacodynamics of chlorambucil delivered in parenteral emulsion

International Journal of Pharmaceutics

Volumn 360, Issue 1-2, 2008, Pages 115-121

  Ganta, Srinivas ^a   Paxton, James W ^a   Baguley, Bruce C ^b   Garg, Sanjay ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Anticancer activity; Chlorambucil; Colon 38 adenocarcinoma; Parenteral emulsion; Pharmacokinetics; Tissue distribution

Indexed keywords

CHLORAMBUCIL; EMULSIFYING AGENT; PHOSPHATIDYLCHOLINE; SOYBEAN OIL; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; C57BL 6 MOUSE; CANCER INHIBITION; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG STABILITY; DRUG TISSUE LEVEL; EMULSION; MALE; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; OSMOLALITY; PARTICLE SIZE; PRIORITY JOURNAL; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; CHEMISTRY, PHYSICAL; CHLORAMBUCIL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; ELECTROCHEMISTRY; EMULSIONS; HYDROGEN-ION CONCENTRATION; INFUSIONS, PARENTERAL; MALE; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; OSMOLAR CONCENTRATION; PARTICLE SIZE; SOLUBILITY; TISSUE DISTRIBUTION;

EID: 47049117837     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.04.027     Document Type: Article

References (34)

1. Ahmed A.E., Koenig M., and Farrish J.H.H. Studies on the quantitation of chlorambucil in plasma by reversed-phase high-performance liquid chromatography. J. Chromatogr. B: Biomed. Appl. 233 (1982) 392-397
2. ® (Chlorambucil) in Current Clinical Guide. 2nd edition (1993), Borroughs Wellcome Co., Oncology Products Wellcome Oncology NCM Publ., New York
3. Benita S., and Levy M.Y. Submicron emulsions as colloidal drug carriers for intravenous administration: comprehensive physicochemical characterization. J. Pharm. Sci. 82 (1993) 1069-1079
4. Collins-Gold L.C., Lyons R.T., and Bartholow L.C. Parenteral emulsions for drug delivery. Adv. Drug Deliv. Rev. 5 (1990) 189-208
5. Couvreur P., Roblot-Treupel L., Poupon M.F., Brasseur F., and Puisieux F. Nanoparticles as microcarriers for anticancer drugs. Adv. Drug Deliv. Rev. 5 (1990) 209-230
6. Dipali S.R., Kulkarni S.B., and Betageri G.V. Comparative study of separation of non-encapsulated drug from unilamellar liposomes by various methods. J. Pharm. Pharmacol. 48 (1996) 1112-1115
7. Dorr R.T., and Fritz W.L. Cancer Chemotherapy Handbook (1982), Elsevier Science, New York
8. Fukui H., Koike T., Nakagawa T., Saheki A., Sonoke S., Tomii Y., and Seki J. Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS (R)), with commercial lipid-based formulations. Int. J. Pharm. 267 (2003) 101-112
9. Galton D.A.G., Israels L.G., Nabarro J.D.N., and Till M. Clinical trials of p-di(2-chloroethylamine)-phenylbutyric acid (CB1348) in malignant lymphoma. BMJ II (1965) 1172
10. Hall A.G., and Tilby M.J. Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Rev. 6 (1992) 163-173
11. Handa T., Saito H., and Miyajima K. Phospholipid monolayers at the triolein-saline interface: production of microemulsion particles and conversion of monolayers to bilayers. Biochemistry 29 (1990) 2884-2890
12. Hansrani P.K., Davis S.S., and Groves M.J. The preparation and properties of sterile intravenous emulsions. J. Parenter. Sci. Technol. 37 (1983) 145-150
13. Higuchi T., and Connors K.A. Phase solubility technique. Adv. Anal. Chem. Instrum. 4 (1965) 117-212
14. Hultin M., Carneheim C., Rosenqvist K., and Olivecrona T. Intravenous lipid emulsions: removal mechanisms as compared to chylomicrons. J. Lipid Res. 36 (1995) 2174-2184
15. Igarashi R., Takenaga M., and Matsuda T. Distribution of lipid microsphere preparations. Adv. Drug Deliv. Rev. 20 (1996) 147-154
16. Ishii F., Sasaki I., and Ogata H. Effect of phospholipid emulsifiers on physicochemical properties of intravenous fat emulsions and/or drug carrier emulsions. J. Pharm. Pharmacol. 42 (1990) 513-515
17. Khandavilli S., and Panchagnula R. Nanoemulsions as versatile formulations for paclitaxel delivery: peroral and dermal delivery studies in rats. J. Invest. Dermatol. 127 (2007) 154-162
18. Kurihara A., Shibayama Y., Mizota A., Yasuno A., Ikeda M., Sasagawa K., Kobayashi T., and Hisaoka M. Enhanced tumor delivery and antitumor activity of palmitoyl rhizoxin using stable lipid emulsions in mice. Pharm. Res. 13 (1996) 305-310
19. Lee F.Y.F., Coe P., and Workman P. Pharmacokinetic basis for the comparative antitumour activity and toxicity of chlorambucil, phenylacetic acid mustard and β,β-difluorochlorambucil (CB 7103) in mice. Cancer Chemother. Pharmacol. 17 (1986) 21-29
20. Lundberg B. Preparation of drug-carrier emulsions stabilized with phosphatidylcholine-surfactant mixtures. J. Pharm. Sci. 83 (1994) 72-75
21. Lundberg B.B., Griffiths G., and Hansen H.J. Conjugation of an anti-B-cell lymphoma monoclonal antibody, LL2, to long-circulating drug-carrier lipid emulsions. J. Pharm. Pharmacol. 51 (1999) 1099-1105
22. Maeda H., and Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Syst. 6 (1989) 193-210
23. Maranhoo R.C., Tercyak A.M., and Redgrave T.G. Effects of cholesterol content on the metabolism of protein free emulsion models of lipoproteins. Biochim. Biophys. Acta 875 (1986) 247-255
24. Mizushima Y., and Hoshi K. Recent advances in lipid microspheres technology for targeting prostaglandin delivery. J. Drug Target 1 (1993) 93-100
25. Patlolla R.R., and Vobalaboina V. Pharmacokinetics and tissue distribution of etoposide delivered in parenteral emulsion. J. Pharm. Sci. 94 (2005) 437-445
26. Sarker D.K. Engineering of nanoemulsions for drug delivery. Curr. Drug Deliv. 2 (2005) 297-310
27. Schiffelers R.M., Fens M.H.A.M., Janssen A.P.C.A., Molema G., and Storm G. Liposomal targeting of angiogenic vasculature. Curr. Drug Deliv. 2 (2005) 363-368
28. Seki J., Sonoke S., Saheki A., Fukui H., Sasaki H., and Mayumi T. A nanometer lipid emulsion, lipid nano-sphere (LNS), as a parenteral drug carrier for passive drug targeting. Int. J. Pharm. 273 (2004) 75-83
29. Takenaga M. Application of lipid microspheres for the treatment of cancer. Adv. Drug Deliv. Rev. 20 (1996) 209-219
30. Wu J., Lee A., Lu Y., and Lee R.J. Vascular targeting of doxorubicin using cationic liposomes. Int. J. Pharm. 337 (2007) 329-335
31. Yamaguchi H., Watanabe K., Hayashi M., and Awazu S. Effect of egg yolk phospholipids plasma elimination and tissue distribution of coenzyme Q10 administered in an emulsion to rats. J. Pharm. Pharmacol. 36 (1984) 768-769
32. Yamaguchi T., Nishizaki K., Itai S., Hayashi H., and Ohshima H. Physicochemical characterization of parenteral lipid emulsion: determination of haymaker constants and activation energy of coalescence. Pharm. Res. 12 (1995) 342-347
33. Yamaguchi T., Tanabe N., Fukushima Y., Nasu T., and Hayashi H. Distribution of prostaglandin E1 in lipid emulsions in relation to release rate from lipid particles. Chem. Pharm. Bull. 42 (1994) 646-650
34. Zara G.P., Bargoni A., Cavalli R., Fundarò A., Vighetto D., and Gasco M.R. Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. J. Pharm. Sci. 91 (2002) 1324-1333